Form 13-F position report

2SEVENTY BIO INC

Reported by NORTHERN TRUST CORPORATION

TSVT CUSIP 901384107 Manager CIK 0000073124

Reported 347,440 shares, up 126,092 (57.0%) from the prior quarter.

Reported value 21.4%; share count 57.0% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 347,440 Quarter-end amount reported
Reported value $4,586,000 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5713000
2022-03-31 3777000
2022-06-30 4586000
2022-09-30 5000000
2022-12-31 3350422
2023-03-31 3569979
2023-06-30 4633483
2023-09-30 1767050
2023-12-31 1789116
2024-03-31 2271910
2024-06-30 1593781
2024-09-30 1900334
2024-12-31 1199762
2025-03-31 1970615
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for 2SEVENTY BIO INC held by NORTHERN TRUST CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -398,910 (-100.0%) 0 $0 2025-08-13
Q1 2025 Reduced 398,910 -9,173 (-2.2%) < 0.01% $1,970,615 2025-05-13
Q4 2024 Added 408,083 +5,470 (1.4%) < 0.01% $1,199,762 2025-02-14
Q3 2024 Reduced 402,613 -11,356 (-2.7%) < 0.01% $1,900,334 2024-11-13
Q2 2024 Reduced 413,969 -10,687 (-2.5%) < 0.01% $1,593,781 2024-08-14
Q1 2024 Added 424,656 +5,659 (1.4%) < 0.01% $2,271,910 2024-05-14
Q4 2023 Reduced 418,997 -31,781 (-7.1%) < 0.01% $1,789,116 2024-02-13
Q3 2023 Reduced 450,778 -7,076 (-1.5%) < 0.01% $1,767,050 2023-11-13
Q2 2023 Added 457,854 +107,856 (30.8%) < 0.01% $4,633,483 2023-08-11
Q1 2023 Reduced 349,998 -7,571 (-2.1%) < 0.01% $3,569,979 2023-05-15
Q4 2022 Added 357,569 +13,938 (4.1%) < 0.01% $3,350,422 2023-02-13
Q3 2022 Reduced 343,631 -3,809 (-1.1%) < 0.01% $5,000,000 2022-11-14
Q2 2022 Added 347,440 +126,092 (57.0%) < 0.01% $4,586,000 2022-08-12
Q1 2022 Reduced 221,348 -1,532 (-0.7%) < 0.01% $3,777,000 2022-05-13
Q4 2021 New 222,880 +222,880 (0.0%) < 0.01% $5,713,000 2022-02-08

Who else reported the position

146 managers reported 2SEVENTY BIO INC for Q2 2022.

Managers reporting 2SEVENTY BIO INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
EcoR1 Capital LLC Unchanged 3,495,943 0 1.59% $46,146,000 3 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 2,905,367 +393,412 < 0.01% $38,351,000 3 qtrs
BlackRock Inc Added 2,528,841 +935,077 < 0.01% $33,382,000 3 qtrs
STATE STREET CORPORATION Reduced 2,491,623 -668,353 < 0.01% $32,889,000 3 qtrs
VANGUARD GROUP INC Added 2,330,083 +949,757 < 0.01% $30,758,000 3 qtrs
BAKER BROS ADVISORS LP Unchanged 2,062,744 0 0.15% $27,228,000 3 qtrs
ARMISTICE CAPITAL LLC Reduced 1,600,000 -400,000 0.37% $21,120,000 3 qtrs
Madison Avenue Partners LP Added 1,511,300 +614,328 4.08% $19,949,000 2 qtrs
Bain Capital Life Sciences Investors LLC Unchanged 1,408,901 0 2.18% $18,597,000 3 qtrs
Newtyn Management LLC Reduced 1,346,796 -241,009 3.37% $17,778,000 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
12,329
Shared
335,111
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.